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CASE REPORT
Thyrotoxic crisis presenting 
with jaundice
R. D. S. S. Wickramasinghe1, W. A. N. V. Luke2*, B. S. Sebastiampillai1, M. P. M. L. Gunathilake1 and R. Premaratna3
Abstract 
Background: Thyrotoxic crisis is a medical emergency requiring early diagnosis and urgent management, which can 
be challenging due to its diverse clinical presentations. While common presentations include fever, sweating, palpita-
tions, tremors and confusion, presence of jaundice is rare.
Case presentation: We report a 35-year-old male who presented with jaundice due to cholestasis along with other 
features of thyrotoxic crisis due to Graves’ disease. He had a good clinical recovery with resolution of cholestasis fol-
lowing treatment for thyrotoxic crisis.
Conclusion: Jaundice can be a rare manifestation of thyrotoxic crisis, and should be considered in the differential 
diagnosis when other clinical features of thyrotoxic crisis are present. However secondary causes of jaundice should 
be looked into and excluded.
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Background
Thyrotoxic crisis is an acute life threatening hyper-met-
abolic state precipitated by excessive release of thyroid 
hormones. Fever, tachycardia and hypertension with 
neurological and gastrointestinal symptoms are the com-
monly encountered clinical features. Thyrotoxic crisis 
warrants urgent diagnosis and commencement of treat-
ment in order to reduce associated mortality.
Although hepatic dysfunction can be associated with 
thyrotoxic crisis, it is important to ascertain the etiol-
ogy of jaundice and liver derangement as drug induced 
cholestasis, autoimmune liver disease and sepsis related 
hepatic dysfunction warrant specific management.
Case presentation
A 35-year-old Asian male presented with fever, jaundice, 
loose stools, palpitations, bilateral ankle swelling, short-
ness of breath, agitation and tremulousness following a 
brief illness with cough and cold. He was diagnosed to 
have thyrotoxicosis due to Graves’ disease 2  years back 
and had defaulted treatment with carbimazole and pro-
pranolol after 6 months. He did not give a history of pre-
vious hepatitis infections or blood transfusions. He had 
no exposure history for leptospirosis or other etiological 
agents of acute hepatitis such as intravenous drug abuse, 
risky sexual encounters or consumption of street food. 
He denied any hepatotoxic drug treatment, and had no 
history of joint pains or facial rashes. He had no past 
history of other chronic diseases. He consumed alcohol 
occasionally and the last alcohol consumption was about 
2 months prior to his current presentation.
On admission, he was febrile (101.6 °F) and had dysp-
noea, deep icterus, tremulousness, sweaty skin and bilat-
eral pitting ankle oedema. He had exophthalmos but no 
proptosis, lid lag or external opthalmoplegia. The thyroid 
gland was diffusely enlarged and there was no lymphad-
enopathy. He was conscious and rational with no focal 
neurological deficits. His Jugular venous pressure was 
elevated 8 cm above the sternal angle and the pulse rate 
was 120/min and irregularly irregular. The blood pressure 
was 150/70  mmHg. Examination of the lungs revealed 
end inspiratory bi-basal fine crepitations. The examina-
tion of abdomen was unremarkable except for mild ten-
derness over right hypochondrium.
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His laboratory investigation results were as follows; 
white cell count was 2.9  ×  103/mL, platelets 59  ×  103/
mL, haemoglobin 11.1 g/dL, haematocrit 32.5 % suggest-
ing bi-cytopenia and blood picture had no evidence of 
microangiopathic haemolytic anaemia. Urine full report 
was normal except for a trace of albumin. Serum sodium 
137  mmol/L, potassium 3.9  mmol/L and creatinine 
64  µmol/L (60–115). The liver functions; aspartate ami-
notransferase (AST) 71 U/L (0–40), alanine aminotrans-
ferase (ALT) 35  U/L (0–40), alkaline phospatase (ALP) 
259  U/L (34–104), total bilirubin 72.9  µmol/L (1–23.9), 
direct bilirubin 39.2  µmol/L, γglutamyltransferase 
149 U/L (7–50) suggesting cholestasis. His blood culture 
was sterile. Serum calcium 2.04 mmol/L (2.10–2.54) and 
magnesium 0.8  mmol/L (0.7–0.9). C-reactive protein 
10.64  mg/L (0.00–5.00) and ESR 42  mm/1st  h. His thy-
roid stimulating hormone (TSH) 0.01 mIU/L (0.35–4.94), 
free T4 5.14 ng/dL (0.70–1.48). Ultrasound scan of neck 
revealed defuse enlargement of thyroid gland with no 
nodules or enlarged cervical lymph nodes. TSH receptor 
antibodies were positive with a titre of 6.08 U/L (positive 
>1.75), suggesting thyrotoxicosis secondary to Graves’ 
diseases. He was negative for hepatitis A IgM, hepatitis B 
surface antigen (HBsAg), cytomegalo virus (CMV) IgM, 
Epstein barr (EBV) IgM, leptospirosis antibodies and anti-
nuclear antibodies. He was not checked for Hepatitis E as 
it is extremely rare in Sri Lanka. The ECG showed atrial 
fibrillation with rapid ventricular response, chest radiog-
raphy showed cardiomegaly with upper lobe diversion and 
2D echocardiography revealed global cardiac dysfunction 
with ejection fraction of 50 %, suggesting possible thyro-
toxic cardiomyopathy. Serial ECGs did not show evidence 
of dynamic ischemic changes and cardiac biomarkers 
were negative for an acute coronary event. He was treated 
as thyrotoxic crisis with atrial fibrillation leading to heart 
failure precipitated by lower respiratory tract infection in 
addition to deranged liver functions with no acute liver 
failure. Therefore the medical management included 
oral high dose carbimazole (45 mg/day), intravenous (iv) 
hydrocortisone 100  mg 8 hourly, iv cefuroxime 750  mg 
8 hourly, and oral clarithromycin 500  mg twice daily 
and oral bisoprolol 5  mg twice daily. His clinical condi-
tion and liver biochemistry improved with total bilirubin 
coming down to 46.6 µmol/L, AST 27 U/L, ALT 23 U/L 
after 1 week of treatment for thyrotoxicosis (Table 1). He 
was lost to follow up after 4 weeks and it was very sad to 
hear that he had succumbed to a fatal road traffic accident 
while attending to personal activities.
Discussion
This patient had evidence of cholestatic jaundice together 
with thyrotoxic crisis. Occurrence of jaundice is rare with 
thyrotoxic crisis and can be due to various related or 
unrelated conditions. Although this can be due to thyro-
toxic crisis itself, drugs that are used in the treatment of 
hyperthyroidism, other associated autoimmune disorders 
such as auto immune hepatitis (AH) or primary biliary 
cirrhosis (PBC), co-existing disorders such as Gilbert’s 
syndrome, thyrotoxic crisis associated cardiac failure 
causing hepatic congestion or atrial fibrillation result-
ing in hepatic artery clot-embolization may account for 
jaundice. However causes that are unrelated to hyperthy-
roidism such as viral hepatitis, alcohol abuse, sepsis, chol-
angitis and medications such as acetaminophen, isoniazid 
and rifampicin may complicate the picture with jaundice.
Although this patient had an acute respiratory tract 
infection prior to the onset of the illness it is unlikely that 
it would have resulted in a cholestasis. Furthermore he 
had not received any antibiotic such as co-amoxiclav that 
would cause cholestasis. He was also negative for com-
mon hepatitis viruses in Sri Lanka such as hepatitis A, B 
and other hepatotropic viruses such as EBV and CMV. 
Although leptospirosis gives a cholestatic pattern this 
possibility was excluded by serology.
Graves’ disease can be associated with autoimmune 
hepatitis (AIH) and primary biliary cirrhosis (PBC). 
While AIH is commoner in young patients, mainly 
females, PBC is commoner in middle aged females [1, 
2] and they generally present with elevation of hepatic 
transaminases, alkaline phosphatase and gamma gluta-
myltransferase enzymes. Confirmation of AIH and PBC 
require presence of anti-nuclear antibodies and other 
liver specific antibodies like anti-smooth muscle anti-
bodies and anti-mitochondrial antibodies. However anti-
nuclear antibodies were negative in this patient making 
AIH and PBC unlikely. Furthermore his rapid response to 
short course of treatment with low dose steroids make an 
autoimmune aetiology for cholestasis unlikely.
In Gilbert syndrome, there is mild elevation of uncon-
jugated bilirubin without hemolysis or transaminitis and 
is found in 2–13 % of the population [3]. Although they 
can become clinically icteric during stressful disorders, 
they will continue to have unconjugated hyper bilirubi-
naemia rather than rise in conjugated bilirubin. There-
fore it is unlikely that this patient had co-existent Gilbert 
syndrome.
Table 1 Serial biochemical investigations
Investigation Admission Day 3 Day 7 Day 14
AST (u/L) 71 45 27 24
ALT (u/L) 35 33 23 24
Total bilirubin (umol/L) 72.9 64.3 46.6 25
TSH (mIU/L) (0.35–4.94 mIU/L) 0.01
Free T4 (0.70–1.48 ng/dL) 5.14
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Furthermore, altered liver functions are known to 
occur in cardiac failure by two main mechanisms. They 
include liver congestion (congestive hepatomegaly) due 
to severe right heart failure or ischemic hepatitis [4]. 
Congestive hepatomegaly is often associated with mod-
erately elevated transaminases; two to three times the 
upper limit and an increase in both the direct and indi-
rect bilirubin [4]. Clinically these patients have features 
of severe right heart failure with elevated JVP, gross 
oedema and ascites [4]. However, in congestive hepato-
megaly jaundice is a rare finding and the total bilirubin 
level is rarely greater than 50  µmol/L. This patient was 
icteric and had an AST level about two times normal, a 
normal ALT level and serum bilirubin level that is higher 
than what is expected in congestive hepatomegaly. Fur-
thermore his Echocardiographic assessment did not 
reveal severe cardiac dysfunction or right heart failure. 
Therefore, it is unlikely that the hepatic involvement 
and icterus in this patient were due to congestion. On 
the other hand, the hallmark findings of ischemic hepa-
titis are severe jaundice, with a bilirubin level as high as 
250 µmol/L, elevation of AST to more than ten times the 
upper reference range limit [4]. Therefore, in this patient 
the clinical picture and biochemical investigations were 
not suggestive of liver involvement secondary to cardiac 
dysfunction.
Primary hepatic dysfunction was described in patients 
with hyperthyroidism for the first time in 1874 [5]. 
Although there have been further descriptions of similar 
hepatic dysfunction in thyrotoxicosis the reasons behind 
such involvement are yet to be understood. There are 
several hypotheses proposed as the cause of cholestasis 
in thyrotoxicosis. Increased hepatic oxygen consump-
tion without a parallel increase in hepatic blood flow in 
hypermetabolic state of hyperthyroidism may result in 
subsequent lowering of oxygen tension in the centrilobu-
lar zones. This may interfere with bile transport resulting 
in cholestasis [6]. However this hypothesis is yet to be 
proven.
Treatment with propylthiouracil has been reported 
to cause liver failure and deaths, especially in children 
[7]. However timely discontinuation of the drug leads to 
complete recovery in most cases [8]. With propylthiou-
racil treatment, a hepatic transaminitis with no elevation 
in bilirubin have been shown in about 30 % of patients 
after 2 months of therapy [9]. However in a majority of 
these patients normalization of transaminitis have been 
documented with further continuation of treatment for 
about 5 months [10]. On the other hand treatment with 
methimazole and carbimazole, has caused alteration 
in liver enzymes only in a few cases. Such alteration is 
thought to be due to a hypersensitivity reaction occur-
ring in patients receiving normal doses of the drug and is 
usually associated with a cholestatic pattern in the liver 
function tests. It is known to occur within 2  weeks of 
initiation of therapy. Hepatic histology of such patients 
have shown cholestasis and non-specific infiltration of 
portal tracts with mono-nuclear cells and eosinophils 
[11].
This patient had a rapid improvement in clinical jaun-
dice and cholestatic picture with specific management 
for thyrotoxic crisis. This suggest that thyrotoxic crisis 
itself as the most likely cause for his clinical picture.
Conclusion
Thyrotoxic crisis, is a life threatening medical condition 
with a diverse clinical picture that require early diagnosis 
and treatment in order to reduce the associated mortal-
ity. Jaundice could rarely occur as part of clinical mani-
festation that improves with the specific management 
of thyrotoxic crisis alone. However careful evaluation in 
order to identify a secondary cause for jaundice may be 
warranted for the effective management.
We have adhered to the CARE guidelines for complete-
ness and transparency of case reports (Additional file 1).
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